Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
Total Valuation
Milestone Pharmaceuticals has a market cap or net worth of $251.25M. The enterprise value is $167.61M.
Market Cap$251.25M
Enterprise Value$167.61M
Share Statistics
Milestone Pharmaceuticals has 85,169,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding85,169,340
Owned by Insiders1.00%
Owned by Institutions10.96%
Financial Efficiency
Milestone Pharmaceuticals’s return on equity (ROE) is -3.16 and return on invested capital (ROIC) is -61.58%.
Return on Equity (ROE)-3.16
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-61.58%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-1.26M
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Milestone Pharmaceuticals is ―. Milestone Pharmaceuticals’s PEG ratio is 0.07.
PE Ratio―
PS Ratio0.00
PB Ratio11.17
Price to Fair Value11.17
Price to FCF-5.08
Price to Operating Cash Flow-5.19
PEG Ratio0.07
Income Statement
In the last 12 months, Milestone Pharmaceuticals had revenue of 0.00 and earned -41.52M in profits. Earnings per share was -0.67.
Revenue0.00
Gross Profit0.00
Operating Income-42.10M
Pretax Income-41.52M
Net Income-41.52M
EBITDA-37.83M
Earnings Per Share (EPS)-0.67
Cash Flow
In the last 12 months, operating cash flow was -43.18M and capital expenditures -33.00K, giving a free cash flow of -43.22M billion.
Operating Cash Flow-43.18M
Free Cash Flow-43.22M
Free Cash Flow per Share-0.51
Dividends & Yields
Milestone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.06
52-Week Price Change34.64%
50-Day Moving Average2.17
200-Day Moving Average1.74
Relative Strength Index (RSI)49.43
Average Volume (3m)3.22M
Important Dates
Milestone Pharmaceuticals upcoming earnings date is Mar 31, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 31, 2026
Ex-Dividend Date―
Financial Position
Milestone Pharmaceuticals as a current ratio of 9.10, with Debt / Equity ratio of 279.05%
Current Ratio9.10
Quick Ratio9.10
Debt to Market Cap0.36
Net Debt to EBITDA-0.70
Interest Coverage Ratio11.76
Taxes
In the past 12 months, Milestone Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate<0.01
Enterprise Valuation
Milestone Pharmaceuticals EV to EBITDA ratio is -4.19, with an EV/FCF ratio of -6.10.
EV to Sales0.00
EV to EBITDA-4.19
EV to Free Cash Flow-6.10
EV to Operating Cash Flow-6.11
Balance Sheet
Milestone Pharmaceuticals has $82.58M in cash and marketable securities with $57.21M in debt, giving a net cash position of $25.38M billion.
Cash & Marketable Securities$82.58M
Total Debt$57.21M
Net Cash$25.38M
Net Cash Per Share$0.30
Tangible Book Value Per Share$0.21
Margins
Gross margin is -0.93%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-0.93%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Milestone Pharmaceuticals is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.50
Price Target Upside86.72% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast3.70%